SELP and COVID-19: Based on our current understanding of the processes of thrombocytopathy and endotheliopathy, which are highlighted in this P-selectin review, drugs targeting platelet activation and death, as well as increasing endothelial cell health, could be useful in treating COVID-19 patients.